---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000114"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:46:27.236959+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunovant announces positive initial Phase 1 data for IMVT-1402 with IgG reductions and no albumin or LDL-C changes

## Summary
- Mean total IgG reduction of 63% after four weekly 300 mg SC doses of IMVT-1402 in Phase 1 MAD cohort.
- No decrease in serum albumin below baseline or increase in LDL-C above baseline observed after 4 weeks.
- Subcutaneous doses of IMVT-1402 achieved peak IgG reductions similar to those previously seen with batoclimab.
- All adverse events were mild or moderate; dosing for 600 mg cohort has recently begun.
- Immunovant hosted a conference call and webcast on September 26, 2023 to discuss the data.

## SEC filing metadata
- accession: 0001764013-23-000114
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000114/0001764013-23-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000114/imvt-20230926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000114
- JSON: https://secwatch.observer/filing/0001764013-23-000114.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.